2 completed. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
Follow fexapotide: new trials by email Literature Review of fexapotide trials Research Report on fexapotide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer NX-1207 2.5 mg, NX-1207 15 mg - Prostate Cancer | Phase 2 | Completed | Nymox Corporation | 141 | 2012-02-21 | 2017-03-10 |
| Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate) 2.5 mg NX-1207, 0.125 mg NX-1207, finasteride - Benign Prostatic Hyperplasia (BPH), Enlarged Prostate | Phase 2 | Completed | Nymox Corporation | 85 | 2007-05-01 | 2012-06-14 |
Prostatic Hyperplasia (1) · Prostatic Neoplasms (1)
United States (2)